

Inside the Issue: Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 Inhibitor

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- In the Phase III DESTINY-Breast04 study evaluating trastuzumab deruxtecan versus treatment of physician's choice for HER2-low metastatic breast cancer (mBC) treated with 1 to 2 lines of chemotherapy in the metastatic setting, which observation was made among patients with HR-positive disease?**
 - Overall survival (OS) and progression-free survival (PFS) were not significantly improved on the trastuzumab deruxtecan arm
 - PFS but not OS was significantly improved on the trastuzumab deruxtecan arm
 - PFS and OS were significantly improved on the trastuzumab deruxtecan arm
- Which of the following drug types best describes camizestrant?**
 - Oral SERD (selective estrogen receptor degrader)
 - mTOR inhibitor
 - Antibody-drug conjugate
 - AKT inhibitor
- The Phase III CAPitello-291 trial evaluating the addition of capivasertib to fulvestrant for patients with recurrent ER-positive, HER2-negative mBC demonstrated which of the following outcomes?**
 - Capivasertib and fulvestrant led to a significant improvement in PFS irrespective of the presence of AKT pathway gene alterations
 - Capivasertib and fulvestrant led to a significant improvement in PFS for only those patients with AKT pathway gene alterations
 - Capivasertib and fulvestrant did not lead to a significant improvement in PFS
- The novel antibody-drug conjugate patritumab deruxtecan is directed against which cellular target?**
 - TROP2
 - PIK3CA
 - HER3
 - AKT
- Which outcome was reported in the Phase III TROPiCS-02 study evaluating sacituzumab govitecan versus treatment of physician's choice for patients with ER-positive, HER2-negative mBC after failure of at least 2 chemotherapy regimens?**
 - OS and PFS were not significantly improved on the sacituzumab arm
 - PFS but not OS was significantly improved on the sacituzumab arm
 - PFS and OS were significantly improved on the sacituzumab arm